Cancer-regenerating cells that arise after chemotherapy have been identified as a new type of cancerous cell that is responsible for the return of acute myeloid leukemia (AML) after remission.
Cancer-regenerating cells that arise after chemotherapy have been identified as a new type of cancerous cell that is responsible for the return of acute myeloid leukemia (AML) after remission.
A study published in Cancer Cell identified leukemic-regenerating cells (LRCs), which are distinct from leukemic stem cells (LSCs). LRCs are transient, can only be detected in a living organism, and are distinct from therapy-naïve LSCs. According to the authors, LRC features can be used as markers of relapse.
Relapse rates in AML after initial treatment range from 40% to 50%, according to Mick Bhatia, PhD, the lead author and director of the McMaster University Stem Cell and Cancer Research Institute, explained that the common belief had been that relapse was caused by dormant cancer stem cells that resisted chemotherapy treatment. It had been difficult to find the cells responsible for relapse because chemotherapy treatment can be so destructive that leftover leukemia cells go undetected.
Read more about interventions for AML after relapse.
“Chemotherapy is not entirely specific and destroys a lot of other tissues, making the patient’s body a difficult place to do the detective work to find cells responsible for relapse,” Bhatia said in a statement. “It’s like trying to find a pen of unknown color or type in an office where a bomb went off. What we were trying to find is what causes the relapse somewhere where a bomb — in this case chemotherapy – had already caused so much collateral damage.”
Using a model of patient leukemic disease in mice, the researchers at McMaster were able to identify when the disease becomes highly regenerative, which sets the stage for eventual relapse. They could distinguish the surviving human leukemic cells from the nondiseased mouse cells.
The new understanding of leukemic regeneration will allow physicians to introduce additional drugs in combination with chemotherapy in order to take advantage of chemotherapy’s benefits while still targeting these altered cancer cells.
“Chemotherapy has increased the number of years cancer patients survive, but if you look at the overall death rates for people with leukemia, they are relatively unchanged,” said Bhatia. “The problem is that the tumor comes back. It’s the relapse, then, that kills the patients. Our goal is to prevent the relapse altogether.”
Reference
Boyd AL, Aslostovar L, Reid J, et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell. 2018;34(3):483-498. doi: 10.1016/j.ccell.2018.08.007.
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Review Explores Link Between Tumor Burden, CAR T-Cell Therapy Efficacy
November 17th 2023A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.
Read More
High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds
November 3rd 2023A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.
Read More